Paula Paulo graduated in Biotechnology Engineering in 2003 by Instituto Politécnico de Bragança. After that, she moved to Porto to develop a Master Degree in Molecular Oncology (Faculty of Medicine, University of Porto) at IPATIMUP, in collaboration with Michael Hollingsworth’s lab at the University of Nebraska Medical Center (Omaha, USA). This first contact with cancer research set a stone in her professional career, leading her to pursue a PhD in Biomedical Sciences at the School of Medicine and Biological Sciences (ICBAS, University of Porto). She was accepted at the Cancer Genetics Group of IPO Porto, led by Professor Manuel Teixeira, where she started her scientific career in prostate cancer. She completed her PhD in 2011, in tight collaboration with Ragnhild Lothe’s lab at the Oslo University Hospital (Olso, Norway), establishing the existence of different molecular subtypes of prostate cancer considering the presence of genomic rearrangements involving members of the ETS family of transcription factors. Since 2019, she is Assistant Researcher at the Cancer Genetics Group of IPO Porto, specialised in molecular and cellular biology of prostate cancer (Scopus h-index 23). Her main research focus is the identification of genetic alterations in prostate cancer with potential utility for the diagnosis and treatment of the patients. She is particularly interested in the identification of new therapeutic approaches for specific molecular changes/cancer subtypes and in understanding the role of the immune system in therapeutic efficacy. Paula has authored/co-authored 47 articles in international peer-reviewed scientific journals and is actively involved in contributing to the growth of young scientists by supervising PhD and Master students.